美股异动 | Wegovy口服药在美国上市 诺和诺德(NVO.US)盘前续涨超4%

Core Viewpoint - Novo Nordisk (NVO.US) has seen a pre-market increase of over 4% on Tuesday, following an 8% rise over the previous two trading days, currently priced at $57.33 [1] Group 1: Product Launch - Starting January 5, Novo Nordisk will offer two oral weight loss medications, Wegovy, to self-paying patients in the U.S., with monthly prices set at $149 for the 1.5 mg and 4 mg doses [1] - Additionally, two higher-dose oral formulations—9 mg and 25 mg—will be launched at a monthly price of $299 [1] - The price for the 4 mg dose will increase to $199 per month starting April 15 [1] Group 2: Regulatory Approval and Market Position - The U.S. Food and Drug Administration (FDA) approved the oral medication for market release on December 22 of the previous year [1] - This product launch is expected to provide Novo Nordisk with a renewed competitive edge against Eli Lilly (LLY.US) in the market [1]